# GEORGIA BOARD OF PHARMACY 2 MLK Jr. Drive, SE, 11<sup>th</sup> Floor, East Tower Atlanta, GA 30334 May 24, 2023 9:00 a.m.

The following Board members were present:

Michael Azzolin, President Chuck Page, Vice-President Jim Bracewell Michael Brinson Young Chang Cecil Cordle Michael Farmer Dean Stone **Staff present:** 

Eric Lacefield, Executive Director
Dennis Troughton, Director, GDNA
Michael Karnbach, Deputy Director, GDNA
Erick Durham, Special Agent, GDNA
Max Changus, Senior Assistant Attorney General
Kimberly Emm, Assistant Attorney General
Elizabeth Simpson, Assistant Attorney General
Clint Joiner, Attorney
Brandi Howell, Business Support Analyst I

**Visitors:** 

Becca Hallum, GHA
Travis Clark, CAPS-Norcross
Merrilee Gober, MAG
Jenny Danker, GHA
Michael Troidl, Walgreens
Jordan Khail, UGA
Andrew Turnage, GMCC
Helen Sloat, Nelson Mullins
Melissa Reybold, GPhA
Susan DelMonico, Genoa
Serreen Meki, Chilivis Grubman
Heather Hughes, Publix
Mary Kate Snead, Guardian LTC

# **Open Session**

President Azzolin established that a quorum was present and called the meeting to order at 9:00 a.m.

#### **Approval of Minutes**

Mr. Bracewell made a motion to approve the Public and Executive Session minutes from the April 12, 2023, meeting. Mr. Stone seconded, and the Board voted unanimously in favor of the motion.

#### **Report of Licenses Issued**

Mr. Stone made a motion to ratify the list of licenses issued. Mr. Cordle seconded, and the Board voted unanimously in favor of the motion.

# **Correspondences**

Correspondence from Elaine Stutman, McKesson Corporation: The Board considered this correspondence regarding the requirements of having two (2) affiliated entities operating within the same facility. Ms. Stutman's correspondence states that they currently have a facility licensed as a 3PL and is

currently storing government owned products. Her correspondence continues to state that they are in the planning stage of having an affiliate company, Cypress Medical Products LLC, take over the facility to operate as a prescription device wholesaler. The letter states the affiliated entities would share the same space and would have separate employees, operating systems, and IT networks.

Mr. Lacefield stated that, from the staff's perspective, they wanted to make sure they understood the scenario described in the letter. He further stated that they have two (2) separate licenses under the same roof with no wall separating the two facilities. He added that it is his understanding they will have two (2) separate suite numbers. He stated that staff would like to know if this would be permissible or not.

Director Troughton commented by stating that GDNA has not seen two (2) permits sharing the same space. He added that the correspondence states that the storage area for the USG (U.S. Government) products under the 3PL license would be separated from the Cypress area with fencing. He stated that they have one (1) area closed in by fence, but it sounds like everything else will be utilized by everyone. Director Troughton stated that he has not seen the Board allow any two (2) licenses to share the same space, with the exception of retail and hospital.

President Azzolin stated that he has seen wholesale licenses in hospital pharmacies and seen that required by inspectors. Director Troughton affirmed that was correct; however, he stated that he was speaking about a situation outside of a pharmacy having an extra retail or wholesale license.

Discussion was held regarding if an issue were to arise, such as a burglary, GDNA would need to know the inventory is separate and the record keeping would need to be completely separate. Director Troughton stated that he was unsure as to how there would be two (2) suite numbers sharing the same space.

Vice-President Page inquired if they would share common inventory at some point. Director Troughton stated that, based on the information provided in the letter, the 3PL inventory will be behind the fence. He added that he felt that there was not enough information provided in the letter. Mr. Bracewell made a motion to direct GDNA to inspect the space and report back to the Board. Mr. Stone seconded the motion. Discussion was held. Mr. Changus commented that there is no legal prohibition on this so once any enforcement or security concerns have been resolved, they will be obligated to comply with the law and rules. He added that it would be worth GDNA conducting an inspection. There being no further discussion, the motion passed.

Correspondence from Maria Cauchi, Boston Biopharma: The Board considered this correspondence requesting guidance in relation to the wholesale distribution of drugs in the State of Georgia. Vice-President Page commented that there are so many legal interpretations regarding this and he is unsure if the Board should provide any interpretation of the rules for them.

President Azzolin read question #3 of the correspondence:

"In case of a virtual wholesale drug distributor, that handles only procurement, transportation and distribution activities (i.e. no storage/warehousing) and does not handle the product physically at any step of the supply/distribution process: should the premises of such a virtual wholesaler contain a space (e.g. fireproof cabinet or refrigerator) for storing drugs? (for potential sample storage - e.g. samples of defective products that are under investigation due to a customer complaint)"

President Azzolin stated that, since they appear to be virtual only with no handling of drugs, it appears to be like a brokering scenario. He inquired if a license would be needed. Director Troughton agreed that it sounds like they are brokering. He stated that virtual wholesalers starting showing up in the 2000's. He added that virtual wholesalers have always had to meet the minimum qualifications to be a wholesaler. He continued by stating that once they get the wholesaler license, they could start storing drugs in Georgia.

Discussion was held regarding brokering and what is considered brokering.

President Azzolin inquired if the facility is doing the transporting. Director Troughton responded by stating that it appears they are arranging it. He continued by stating that if they are at some point owning the product, brokering the product, etc., they are required by Georgia law to obtain a wholesaler permit. He stated that there have been many virtual wholesalers in Georgia that have obtained the space, the equipment, etc., and obtained a wholesale permit and have never touched the product. He explained that in order to have that license, they have to meet the minimum qualifications.

President Azzolin stated that the correspondence reads, "In case of a virtual wholesale drug distributor, that handles only procurement, transportation and distribution activities...". Director Troughton commented that from GDNA's standpoint, they would need a wholesaler permit to work under this business model.

After further discussion, Mr. Stone made a motion to direct staff to respond to Ms. Cauchi by stating that the Board suggests she adhere to the requirements of the law and rules in the State of Georgia. Additionally, if she needs further clarification, she should consult with her own legal counsel for opinions and interpretations of the laws and rules. Mr. Farmer seconded, and the Board voted unanimously in favor of the motion.

# Georgia Drugs and Narcotics Agency - Mr. Dennis Troughton

Director Troughton introduced Special Agent Eric Durham to the Board.

Director Troughton reported that GDNA conducted 2523 inspections and received 428 complaints for FY2023.

# Attorney General's Report - Mr. Max Changus

No report.

# Executive Director's Report - Mr. Eric Lacefield

**Continuing Education Report:** Mr. Stone made a motion to ratify the below continuing education programs approved since the previous meeting. Mr. Cordle seconded, and the Board voted unanimously in favor of the motion.

Date of Program	Hours	Sponsoring Group	Program Title	CE Code
06/07/2023	.5	The Medical Center, Navicent	Type 1 Diabetes	2023-0004
		Health		

**June Meeting:** Mr. Lacefield reported that a public hearing regarding the low THC rules would be held on June 14<sup>th</sup> at the University of Georgia. He stated that everyone is welcome to participate in that hearing. He added that the Board office is currently accepting written comments concerning the rules and the Notice of Public Hearing is posted on the Board's website. Mr. Lacefield stated that the Executive Director of the Georgia Access to Medical Cannabis Commission, Mr. Andrew Turnage, was present at the Board's meeting in support of the Board and its work. Mr. Lacefield added that he and Mr. Cordle would be joining the Commission's meeting scheduled for later that afternoon to advise them of the Board's proposed rules and hearing.

# **Legal Services – Mr. Clint Joiner**

Mr. Joiner provided the Board with an update on the following rules, along with the effective date:

Rule	Title	<b>Effective Date</b>
480-204	Examinations	May 24, 2023
480-205	Reciprocity	May 24, 2023

480-206	Temporary Licenses	May 24, 2023
480-1001	Controlled Substances and Dangerous Drugs Inspection, Retention of Records and Security	May 24, 2023
480-1102	Compounded Drug Preparations	May 24, 2023
480-3601	Definitions	May 24, 2023
480-3602	Licensing	May 24, 2023
480-3603	Personnel and Supervision	May 24, 2023
480-3604	Policy and Procedures	May 24, 2023
480-3605	Record Keeping	May 24, 2023
480-3606	Patient Counseling	May 24, 2023
480-3607	Notification to Patients	May 24, 2023
480-1002	Prescription Department, Requirement, Supervision, Hours Closed	June 9, 2023
480-1006	Licensure, Applications, and Display of License and Renewal Certificate	June 9, 2023
480-2212	Requirements of Prescription Drug Orders as Issued by PA or APRN Licensed in GA	June 9, 2023
480-2701	Definitions	June 9, 2023
480-2702	Prescription Drug Order Requirements	June 9, 2023
480-2704	Use of Facsimile Machine to Transmit or Receive Prescription Drug Order	June 9, 2023
480-2705	Record-Keeping When Utilizing an Automated Data Processing System	June 9, 2023

#### Miscellaneous

**Misfill Courses:** Vice-President Page requested the Board table its discussion on this topic until its June meeting to allow for additional time for him to conduct further research.

Rule 480-24-.04 Drug Distribution and Chapter 480-24 Nursing Homes, Long Term Care Facilities and Hospice Emergency Drug Kits: These topics were tabled at the Board's April meeting to allow additional time to review the information regarding Chapter 480-24 submitted to Mr. Brinson by Ms. Stephanie Kirkland. President Azzolin asked if there were any comments. Mr. Stone commented that this topic was brought up due to prescription drug orders associated with chart orders and the issues tied to those.

President Azzolin stated that when retail pharmacies traditionally get a prescription, whether it is eprescribed or on paper, many times in nursing homes the physicians are writing on a chart like they would in a hospital. He further stated that it causes workflow issues to duplicate that onto an actual prescription. He added that sometimes pharmacies receive those chart orders and they are asking to take those as prescriptions. President Azzolin stated that by amending this rule it allows them to do so.

President Azzolin commented that in Rule 480-24-.04 where it list out the requirements of that chart order, one thing he did not see is the address of the prescribing practitioner. He stated that Rule 480-10-.15(2) requires the name, address of the prescribing practitioner and DEA registration number in the case of controlled substances. He continued by stating that Rule 480-24-.04(1) states in part, "...All drugs supplied to the facility must be obtained from a pharmacy having a retail pharmacy permit." He explained that it is his assumption that the chart order should mirror the requirements, even though it looks different, it should still have all of those same requirement in it because it is a retail pharmacy prescription.

Director Troughton stated that is the nutshell of the problem. He further stated that in the nursing home industry the physician will come in once a month and sign the chart. He added that there is typically a physician who comes in once a month and is contracted with that home, sees the patient, signs off on the chart, or make changes and writes in a new order. He explained that the physician's name is always on there, but they do not have the physician's address listed, which is a problem for the pharmacy from the standpoint of they do not prepare the chart. He added that it is usually not the pharmacy that is providing

the chart set up. Director Troughton stated that he feels the proposed language helps clarify that it is not a necessity for every patient. He further stated that it is a big deal in a nursing home as it will disrupt the flow and the ability to fill those prescriptions for patients. He added that Ms. Kirkland's suggestions are good, but he does have a few suggestions from GDNA's standpoint.

Mr. Changus commented by stating that the Board has been talking about chart orders for years and it be designed in a way to resolve a problem with efficiency in the nursing home context, but it is not anticipated or articulated in the statute. He added that the Board keeps trying to figure out a way to bend this into what is typically the standard prescription drug order which is what you see in the retail rule. He added that when Mr. Henderson was on the Board, he was championing this for that industry. He inquired if it depends on what the setting is and wanting it to be expansive, but the question is can it be done.

Director Troughton stated that Mr. Joiner looked and "Practitioner Drug Order" is already recognized. Mr. Joiner added that it still exists after the latest round of revisions to that exact rule. He stated that the law and the rules clearly recognize that there is a need for something different than just a prescription drug order. He further stated that Rule 480-27-.01(q) defines "Practitioner Drug Order" as "A drug order written in an institutional practice/setting in a patient's chart for a specific patient. It is not necessary to reduce to writing as required for a prescription drug order." He explained that the Boards rule recognize that as something different.

President Azzolin stated that he does not want the current Board to interpret the rule one way and say it is permissible to not have the address on the prescription and then a future Board interpret it completely different. He further stated that if there is language that clarifies that it is not required to be reduced to a prescription, then it opens up the leeway for this labeling scenario relative to a chart order to be appropriate. Mr. Joiner responded by stating that because of the way it is done and it is not directly addressed, that does muddy the water a bit, but appears to be authorized in the statute and Rule 480-27-.01.

Mr. Stone stated that it seems "Practitioner Drug Order" fits across all boundaries. Mr. Joiner stated that O.C.G.A. § 26-4-80(n) states, "Institutions including, but not limited to, hospitals, long-term care facilities, and inpatient hospice facilities which utilize electronic medical record systems that meet the information requirements for prescription drug orders for patients pursuant to this Code section shall be considered to be in compliance with this Code section."

Mr. Changus stated that he believes it is a question of how far it extends because it talks about institutional settings and the Board may not want to move it beyond what is described in the statute. Director Troughton commented that the only place GDNA sees the problems is in nursing homes and potentially assisted living facilities, which numerous agencies recognize as an institutional type setting. He stated that he thinks it is easier to keep it as an institutional setting and if GDNA sees anything outside of that GDNA will let them know.

After further discussion, the Board directed staff to review the draft provided and bring back to the Board at its June meeting for a vote to post. Director Troughton commented that the enforcement of this will not change based on everything discussed today.

Mr. Brinson thanked Ms. Kirkland for the job she did on the draft.

**Application for Certification of DTM:** At its April meeting, the Board requested staff modify the application by striking #9-15 and adding space for multiple locations. Mr. Stone made a motion to approve the draft as presented. Vice-President Page seconded, and the Board voted unanimously in favor of the motion.

Georgia Pharmacy Convention: Mr. Brinson reminded the members of the Board and the members of the public that the convention is scheduled in June.

Mr. Stone made a motion and Mr. Brinson seconded, and the Board voted to enter into Executive Session in accordance with O.C.G.A. § 43-1-19(h) and § 43-1-2(h) to deliberate and to receive information on applications, investigative reports, and the Assistant Attorney General's report. Voting in favor of the motion were those present who included Michael Azzolin, Jim Bracewell, Michael Brinson, Young Chang, Cecil Cordle, Michael Farmer, Chuck Page, and Dean Stone.

#### **Executive Session**

### Appearance

R.A.F.

# Georgia Drugs and Narcotics Agency - Mr. Dennis Troughton

No report.

# Cognizant's Report - Mr. Chuck Page

- **GDNA Case # T34734**
- **GDNA Case # A34538**
- GDNA Case # A34707
- GDNA Case # A34735
- GDNA Case # A34751
- GDNA Case # A34743
- GDNA Case # A34755
- GDNA Case # B34657
- GDNA Case # B34676
- GDNA Case # B34705
- GDNA Case # B34712
- GDNA Case # B34737
- GDNA Case # A34754
- GDNA Case # A34719
- GDNA Case # B34689
- GDNA Case # B34504 GDNA Case # B34606
- GDNA Case # B34645
- GDNA Case # B34605 GDNA Case # B34699
- GDNA Case # B34673
- GDNA Case # B34700
- GDNA Case # B34653
- GDNA Case # B34713
- **GDNA Case # T34750**

# Attorney General's Report - Mr. Max Changus

Mr. Changus presented the following consent orders for acceptance:

- B.C.D.
- N.A.G.
- S.K.Y.

- C.V.S.P.
- C.V.S.P.
- C.V.S.P.
- C.V.S.P.
- C.P.I.
- D.P.
- S.M.S.H.H.I.
- R.P.
- R.P.I.
- M.B.
- L.C.C.
- M.S.S.
- G.D.C.

# Ms. Emm discussed the following case:

• P.P.A.P.

Ms. Simpson discussed the following cases:

- D.P.I.
- Y.B.

# Executive Director's Report - Mr. Eric Lacefield

• J.D.F.

# <u>Legal Services – Mr. Clint Joiner</u>

No report.

# **Applications**

- M.S.L.
- K.C.N.
- G.L.S.
- C.N.B.
- A.S.B.
- R.C.C.
- Q.B.
- D.D.R.
- C.J.S.
- M.S.C.
- C.M.R.
- J.N.T.
- S.Y.N.
- S.E.D.
- O.A.A.
- A.M.L.
- B.E.H.
- J.R.A.
- D.R.R.
- S.J.L.
- W.S.

- M.M.S.I.
- M.M.S.M.S.I.
- M.M.S.I.
- M.M.S.I.
- M.M.S.I.
- M.M.S.I.
- P.D.S.I.
- P.D.S.I.
- P.D.S.I.
- P.D.S.I.
- P.D.S.I.
- P.D.S.I.
- P.V.S.I.
- P.V.S.I.
- B.I.
- D.H.L.S.C.
- D.H.L.S.C.
- E.I.
- M.M.S.G.S.
- M.M.S.I.
- A.U.S.A.I.
- B.D.D.C.
- B.D.C.
- B.M.
- A.P.
- R.C.M.
- C.N.A.
- C.N.A.
- C.N.A.
- C.N.A.
- C.N.A.
- D.P.S.
- D.P.S.
- Z.H.
- Z.H.
- K.F.F.
- P.P.S.
- P.H.P.
- A.H.G.I.
- A.H.I.I.
- A.O.N.P.
- W.P.C.S.
- P.P.A.P.
- C.A.P.S.I.
- B.U.S.I.
- B.U.S.I.
- B.U.S.I.
- B.U.S.I.

# Correspondences/Requests

- A.
- H.D.M.P.
- M.C.P.S.I.
- K.P.S.A.R.C.
- P.P.I.
- A.S.H.
- K.R.T.
- B.T.H.
- P.J.W.
- R.N.S.
- K.A.M.
- V.A.O.
- R.A.H.
- S.C.B.
- P.A.H.

No votes were taken in Executive Session. President Azzolin declared the meeting back in Open Session.

# **Open Session**

#### Miscellaneous

**Newsletter:** Vice-President Page commented that he, along with Mr. Chang, have been putting together the newsletter for the past year and now that he is Cognizant, it is time consuming to do both. Mr. Farmer agreed to take Vice-President Page's place regarding the newsletter.

Mr. Chang discussed utilizing NABP services for the newsletter. He explained that NABP uses a standard template and the Board sends them the content for the newsletter. He stated that he will check with NABP to see if there is a fee for doing so.

Mr. Stone made a motion for the full Board to take the following actions:

### **Appearance**

• R.A.F. Request to reinstate pharmacist license Refer to the Department of Law

# Georgia Drugs and Narcotics Agency - Mr. Dennis Troughton

No report.

#### Cognizant's Report – Mr. Chuck Page

<u> </u>	Zunt 5 Report 1911: Chuck 1	<u>a uge</u>
•	GDNA Case # T34734	Accept Voluntary Surrender
•	GDNA Case # A34538	Refer to the Department of Law
•	GDNA Case # A34707	Refer to the Department of Law
•	GDNA Case # A34735	Refer to the Department of Law
•	GDNA Case # A34751	Letter of Concern to pharmacy/Refer to the Department of Law for pharmacy technician
•	GDNA Case # A34743	Board directed staff to notify the pharmacy that the lockbox being utilized is not sufficient and remind them that Board approval is required before the pharmacy can utilize a different lockbox.
•	GDNA Case # A34755	Refer to the Department of Law

Refer to the Department of Law GDNA Case # B34657 Misfill Guidance #1A GDNA Case # B34676 GDNA Case # B34705 Close with Letter of Concern GDNA Case # B34712 Close with Letter of Concern GDNA Case # B34737 Close with Letter of Concern GDNA Case # A34754 Refer to the Department of Law Refer to the Department of Law GDNA Case # A34719 GDNA Case # B34689 Misfill Guidance #1A GDNA Case # B34504 Close with no action GDNA Case # B34606 Close with no action GDNA Case # B34645 Close with no action GDNA Case # B34605 Close with no action GDNA Case # B34699 Close with no action GDNA Case # B34673 Close with no action **GDNA Case # B34700** Close with no action GDNA Case # B34653 Close with no action GDNA Case # B34713 Close with no action **GDNA Case # T34750** Accept Voluntary Surrender

# Attorney General's Report – Mr. Max Changus

Mr. Changus presented the following orders for acceptance:

•	B.C.D.	Private Consent Order accepted
•	N.A.G.	Public Consent Order accepted
•	S.K.Y.	Public Consent Order accepted
•	C.V.S.P.	Private Consent Order accepted
•	C.V.S.P.	Public Consent Order accepted
•	C.V.S.P.	Public Consent Order accepted
•	C.V.S.P.	Private Consent Order accepted
•	C.P.I.	Public Consent Order accepted
•	D.P.	Private Consent Order accepted
•	S.M.S.H.H.I.	Private Consent Order accepted
•	R.P.	Public Consent Order accepted
•	R.P.I.	Private Consent Order accepted
•	M.B.	Voluntary Cease & Desist Order accepted
•	L.C.C.	Private Consent Order accepted

Ms. Emm discussed the following case:

M.S.S.

G.D.C.

• P.P.A.P. Table to allow additional time to review

Private Consent Order accepted

Public Consent Order accepted

Ms. Simpson discussed the following cases:

D.P.I. Accept counterproposalY.B. Deny counterproposal

# Executive Director's Report - Mr. Eric Lacefield

• J.D.F. Pharmacist Reinstatement Table pending receipt of additional information

# <u>Legal Services – Mr. Clint Joiner</u> No report.

# **Applications**

)PH	<u>cauons</u>		
•	M.S.L.	Pharmacy Technician	Approved for registration
•	K.C.N.	Pharmacy Technician	Approved for registration
•	G.L.S.	Pharmacy Technician	Table pending receipt of additional information
•	C.N.B.	Pharmacy Technician	Table pending receipt of additional information
•	A.S.B.	Pharmacy Technician	Approved for registration
•	R.C.C.	Pharmacy Technician	Approved for registration
•	Q.B.	Pharmacy Technician	Approved for registration
•	D.D.R.	Pharmacy Technician	Approved for registration
•	C.J.S.	Pharmacy Technician	Approved for registration
•	M.S.C.	Pharmacy Technician	Denied application
•	C.M.R.	Pharmacy Technician	Approved for registration
•	J.N.T.	Pharmacy Technician Renewal	Approved for renewal
•	S.Y.N.	Pharmacy Technician Renewal	Approved for renewal
•	S.E.D.	Pharmacy Technician Renewal	Approved for renewal
•	O.A.A.	Pharmacist Reciprocity	Approved application
•	A.M.L.	Pharmacist Reciprocity	Approved application
•	B.E.H.	Nuclear Pharmacist	Approved application
•	J.R.A.	Pharmacist Renewal	Approved for renewal
•	D.R.R.	Pharmacist Certification of DTM	Approved application
•	S.J.L.	Pharmacist Certification of DTM	Approved application
•	W.S.	Durable Medical Equipment Supplier	Approved application
•	M.M.S.I.	Wholesaler Pharmacy Renewal	Approved for renewal
•	M.M.S.M.S.I.	Wholesaler Pharmacy Renewal	Approved for renewal
•	M.M.S.I.	Wholesaler Pharmacy Renewal	Approved for renewal
•	M.M.S.I.	Wholesaler Pharmacy Renewal	Approved for renewal
•	M.M.S.I.	Wholesaler Pharmacy Renewal	Approved for renewal
•	M.M.S.I.	Wholesaler Pharmacy Renewal	Approved for renewal
•	P.D.S.I.	Wholesaler Pharmacy Renewal	Approved for renewal
•	P.D.S.I.	Wholesaler Pharmacy Renewal	Approved for renewal
•	P.D.S.I.	Wholesaler Pharmacy Renewal	Approved for renewal
•	P.D.S.I.	Wholesaler Pharmacy Renewal	Approved for renewal
•	P.D.S.I.	Wholesaler Pharmacy Renewal	Approved for renewal
•	P.D.S.I.	Wholesaler Pharmacy Renewal	Approved for renewal
•	P.V.S.I.	Wholesaler Pharmacy Renewal	Approved for renewal
•	P.V.S.I.	Wholesaler Pharmacy Renewal	Approved for renewal
•	B.I.	Wholesaler Pharmacy Renewal	Approved for renewal
•	D.H.L.S.C.	Wholesaler Pharmacy Renewal	Approved for renewal
•	D.H.L.S.C.	Wholeseler Pharmacy Renewal	Approved for renewal
•	E.I.	Wholeseler Pharmacy Renewal	Approved for renewal
•	M.M.S.G.S.	Wholeseler Phermacy Renewal	Approved for renewal
•	M.M.S.I.	Wholeseler Phermacy Renewal	Approved for renewal
•	A.U.S.A.I.	Wholesaler Pharmacy Renewal	Approved for renewal

•	B.D.D.C.	Wholesaler Pharmacy Renewal	Approved for renewal
•	B.D.C.	Wholesaler Pharmacy Renewal	Approved for renewal
•	B.M.	Non-Resident Pharmacy Renewal	Approved for renewal
•	A.P.	Non-Resident Pharmacy Renewal	Approved for renewal
•	R.C.M.	Non-Resident Pharmacy Renewal	Approved for renewal
•	C.N.A.	Non-Resident Pharmacy Renewal	Approved for renewal
•	C.N.A.	Non-Resident Pharmacy Renewal	Approved for renewal
•	C.N.A.	Non-Resident Pharmacy Renewal	Approved for renewal
•	C.N.A.	Non-Resident Pharmacy Renewal	Approved for renewal
•	C.N.A.	Non-Resident Pharmacy Renewal	Approved for renewal
•	D.P.S.	Non-Resident Pharmacy Renewal	Approved for renewal
•	D.P.S.	Non-Resident Pharmacy Renewal	Approved for renewal
•	Z.H.	Non-Resident Pharmacy Renewal	Approved for renewal
•	Z.H.	Non-Resident Pharmacy Renewal	Approved for renewal
•	K.F.F.	Non-Resident Pharmacy Renewal	Approved for renewal
•	P.P.S.	Non-Resident Pharmacy Renewal	Approved for renewal
•	P.H.P.	Non-Resident Pharmacy Renewal	Approved for renewal
•	A.H.G.I.	Non-Resident Pharmacy Renewal	Approved for renewal
•	A.H.I.I.	Non-Resident Pharmacy Renewal	Approved for renewal
•	A.O.N.P.	Non-Resident Pharmacy Renewal	Approved for renewal
•	W.P.C.S.	Non-Resident Pharmacy Renewal	Approved for renewal
•	P.P.A.P.	Non-Resident Pharmacy Renewal	Approved for renewal
•	C.A.P.S.I.	Manufacturing Pharmacy Renewal	Approved for renewal
•	B.U.S.I.	Manufacturing Pharmacy Renewal	Approved for renewal
•	B.U.S.I.	Manufacturing Pharmacy Renewal	Approved for renewal
•	B.U.S.I.	Manufacturing Pharmacy Renewal	Approved for renewal
•	B.U.S.I.	Manufacturing Pharmacy Renewal	Approved for renewal
		•	

# Correspondences/Requests

rre	espondences/Requests		
•	A.	Notice of Discipline	No action
•	H.D.M.P.	Notice of Discipline	No action
•	M.C.P.S.I.	Notice of Discipline	Table pending receipt of additional information
•	K.P.S.A.R.C.	Notice of Discipline	No action
•	P.P.I.	Notice of Discipline	No action
•	A.S.H.	Request for extension of intern license	Approved for extension through 04/30/2024
•	K.R.T.	Request for extension of application date	Approved for extension through 09/07/2023
•	B.T.H.	Request for 5 <sup>th</sup> attempt to retake NAPLEX	Approved request
•	P.J.W.	Request for 4 <sup>th</sup> attempt to retake NAPLEX	Approved request
•	R.N.S.	Request for 5 <sup>th</sup> attempt to retake NAPLEX and request for 4 <sup>th</sup> attempt to retake MPJE	Approved request
•	K.A.M.	Request for 4 <sup>th</sup> attempt to retake MPJE	Approved request
•	V.A.O.	Request for 4th attempt to retake MPJE	Approved request
•	R.A.H.	Correspondence	The Board viewed this correspondence for informational purposes only.

S.C.B. Request to terminate probation Approved request
 P.A.H. Remote order entry Approved request

Mr. Brinson seconded, and the Board voted unanimously in favor of the motion.

There being no further business to discuss, the meeting was adjourned at 1:59 p.m.

The next scheduled meeting of the Georgia Board of Pharmacy will be held on Wednesday, June 14, 2023, at 9:00 a.m. at the University of Georgia College of Pharmacy, 250 W Green St., Athens, GA 30602.

Minutes recorded by Brandi Howell, Business Support Analyst I Minutes edited by Eric Lacefield, Executive Director